GSK Pharma shareholders back Ronojit Biswas’ Board, CFO appointment via postal ballot
Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker
Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The company’s EBITDA margin remained resilient above 20%
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Subscribe To Our Newsletter & Stay Updated